A cross-sectional study, using data from a large national survey performed by Crohn’s and Colitis UK, was conducted to investigate factors associated with coping in IBD patients (n=802, mean age 45.5 years) [1]. Ordinal regression analysis was performed to examine the data.
The multivariable analysis showed that females were at higher risk of reporting coping difficulties than males (OR 1.60). A higher disease activity (OR 2.64) and increased perceptions of disease-related stigma (OR 2.12) were also associated with coping difficulties in this population. A better understanding of the disease (OR 0.81) and a higher level of perceived control over the disease (OR 0.68) were related to fewer difficulties with coping.
The authors argued that interventions targeting the improvement of the psychological wellbeing of IBD patients should address the adjustable factors revealed in this study, such as illness perceptions, and sense of control over the disease. In addition, public awareness on IBD-related stigma should be raised to counter the impact of this factor on patients’ psychological wellbeing. Furthermore, clinicians should take into account that females with a high disease activity are particularly at risk of experiencing difficulties in coping with their disease.
- Marshall J, et al. Coping in Inflammatory Bowel Disease: insights from a national survey. P105, ECCO 2021 Virtual Congress, 2-3 & 8-10 July.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Obesity increases the risk of immunogenicity to adalimumab in IBD Next Article
Multiple-myeloma patients may not mount adequate response to COVID vaccine »
« Obesity increases the risk of immunogenicity to adalimumab in IBD Next Article
Multiple-myeloma patients may not mount adequate response to COVID vaccine »
Table of Contents: ECCO 2021
Featured articles
Biologics Updates
Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD
Ustekinumab safe and effective in elderly CD patients
Early clinical remission and response following risankizumab therapy in CD
Risk of hospitalisation and surgery linked to IBD biological
Obesity increases the risk of immunogenicity to adalimumab in IBD
Improvements in Small Molecules
Upadacitinib meets primary endpoint for moderate-to-severe UC
Promising safety and pharmacokinetic data on BT051 for UC
Surgical closure plus anti-TNF outperforms anti-TNF alone for perianal fistula
Novel Biomarkers
Blood proteins predicting relapse in CD identified
Extracellular RNA has potential as a non-invasive biomarker in IBD
Risk Mitigation
No increased risk of (severe) COVID-19 among IBD patients
Oral faecal microbiota transplant therapy efficacious in UC
Artificial intelligence outperforms human classifying of endoscopic images in UC
Increased risk of rectal cancer after colectomy in IBD
Risk of colorectal cancer is detected by low-pass whole genome sequencing
Large variability in IBD care and education across Europe
Ultra-processed food intake associated with IBD
Factors of coping difficulties in IBD revealed
Related Articles
May 9, 2019
Vedolizumab: Results from the GEMINI programme
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com